Entries by Mark DaFonseca

CoreRx Announces Successful US FDA Inspection of Clearwater Facility

Site Achieves “No Action Indicated” Status CLEARWATER, FL, November 22, 2021, CoreRx is pleased to announce that the U.S. Food and Drug Administration (FDA) has issued their Establishment Inspection Report (EIR) for FEI registration number 3007209985, with the inspection status of NAI (No Action Indicated) following its most recent audit at its Clearwater facility in […]

CoreRx Announces New Leadership of Commercial Team

Leadership appointment follows expansion of BD team CLEARWATER, FL, August 2, CoreRx is pleased to announce the recent appointment of Hank Nowak as the Executive Director, Head of Global Business Development. As CoreRx grows its customer base in the U.S. and Internationally, Hank will lead the go-to-market strategy and business development efforts for the company. […]

CoreRx Adds Investment to Expand Oral Dosage Form Capabilities

Investment Will Enhance Development, Scale-up, and Tech Transfer Capabilities Across its US Sites CLEARWATER, FL, July 1, 2021 – CoreRx, Inc. announced today that it is adding investment in formulation development and manufacturing equipment in both its Clearwater, Florida and San Rafael, California facilities.     Following on from the recently announced acquisition of Nucleo Life Sciences, […]

CoreRx Acquires Nucleo Life Sciences

Acquisition Creates Unparalleled East / West Coast Development Services Presence in the US CLEARWATER, FL, May 24, 2021, CoreRx, Inc. announced today the acquisition of Nucleo Life Sciences, a boutique CDMO based in San Rafael, California. Nucleo complements CoreRx’s development services and capabilities and provides a local site on the US West Coast for development […]

CoreRx Inc. receives approval for Schedule I controlled drug manufacture

Approval now extends ability to develop and manufacture all scheduled drug classifications CLEARWATER, FL, April 30, 2021, CoreRx, Inc., is pleased to announce that they have received approval from the Federal Drug Enforcement Agency (DEA) to develop and manufacture Schedule I controlled substances in their facilities. Schedule I substances are “considered the most dangerous class […]